- Home
- BTBD vs PPBT Comparison
BTBD vs PPBT Comparison
Compare BTBD & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | PPBT |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 7.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTBD | PPBT |
|---|---|---|
| Price | $1.51 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.5K | ★ 782.3K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,038,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.53 |
| 52 Week High | $5.60 | $5.20 |
Technical Indicators
Market Signals| Indicator | BTBD | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 45.28 |
| Support Level | $1.48 | $0.78 |
| Resistance Level | $1.62 | $0.87 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 50.00 | 13.50 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.